Literature DB >> 26099629

Lack of myeloid differentiation primary response protein MyD88 L265P mutation in primary cutaneous marginal zone lymphoma.

I Brenner1, S Roth1, L Flossbach1, M Wobser2, A Rosenwald1,3, E Geissinger1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26099629     DOI： 10.1111/bjd.13960

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  3 in total

Review 1.  [Treatment of indolent cutaneous B‑cell lymphoma].

Authors:  M Wobser
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 2.  MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

Authors:  Ruben A L de Groen; Anne M R Schrader; Marie José Kersten; Steven T Pals; Joost S P Vermaat
Journal:  Haematologica       Date:  2019-11-07       Impact factor: 9.941

3.  Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma.

Authors:  Yong Xu; Jian Li; Jian Ouyang; Juan Li; Jingyan Xu; Qiguo Zhang; Yonggong Yang; Min Zhou; Jing Wang; Cuiling Zhang; Yueyi Xu; Ping Li; Rongfu Zhou; Bing Chen
Journal:  Oncotarget       Date:  2017-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.